Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines During the 2022 U.S. Monkeypox Outbreak: JYNNEOS Vaccine

Details

• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology.
• Description:
  CDC recommends that vaccination with JYNNEOS can be considered for people determined to be at high risk for infection to prevent monkeypox disease.
  
  Vaccination Schedule: JYNNEOS vaccine is licensed as a series of two doses administered 28 days (4 weeks) apart.
  
  The standard regimen involves a subcutaneous (Subcut) route of administration with an injection volume of 0.5mL. The standard regimen is the FDA-approved dosing regimen. Since August 9, 2022, the standard regimen has been authorized for people aged <18 years under an Emergency Use Authorization.
  
  
• Content Notes:
  Interim Guidance -- Duration of Immunity -- Dosing Intervals -- Evidence Quality -- Administration -- Interchangeability of dosing regimens -- Coadministration with other vaccines -- Patient Counseling -- Safety -- Reporting of adverse events -- Resources.
• Subjects:
  Mpox (monkeypox)/prevention & Control Smallpox Vaccine Vaccination
• Document Type:
  Text
• Name as Subject:
  JYNNEOS®
• Genre:
  Webpage
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:9875845fdf4029af0a79ff7fcc0857d5a975f9b05876225d2c08883476e673c0cf6a1e25f03b5e0e6c30abbdd5f2d7787deaea0dad57a3b9dd8045b254862fea
• Download URL:
  https://stacks.cdc.gov/view/cdc/120086/cdc_120086_DS1.pdf
• File Type:
  [PDF - 452.93 KB ]